the program is insolvent. The present value of the promised benefits is much greater than the present value of the revenue that is meant to pay those benefits.

It is really an international issue, and it really is an issue that will impact the United States maybe at some point.

Both the Social Security and Medicare programs face substantial financing shortfalls that require legislative corrections.

They collect nothing. They have nothing--nothing to pass on to their kids.

Lower-income workers have not enjoyed the extension of life expectancy that others have.

I and Ranking Member Pallone felt it important for the members of this subcommittee to hear the pros and cons of potential policies in this space.

Tax increases are not the answer. Tax increases will not bring the spending growth in line with GDP growth, and will be economically destructive.

Any government agency that is purporting to be a data-driven organization should welcome the opportunity to operate in a more transparent manner.

It seems to me in some ways that the State Department is living in some altered state of reality.

This legislation improves the CFPB's rulemaking process by ensuring that its policy prescriptions are supported by objective and unbiased research.

But I am trying to focus on how State Department views Boko Haram and----

Having a child shouldn't mean losing your job. It should not lead to fear and financial dire straits.

It seems that we could come up with something to protect 1.5 percent of the workforce.

Through this effort, Congress hopes to clear a path to find more cures and treatments while also creating jobs and keeping America as the innovation center of the world.

I know people who have died of this rare disease. It is a terrible disease, and yet not once did anyone ever mention at that hearing the possibility of accelerated approval.

I urge the committee to address this crisis head-on, and encourage meaningful development in the antibiotic space.

Today's hearing relates to the 21st Century Cures Initiative announced by the Energy and Commerce Committee on April 30, 2014.

Congress does not have all the answers, but we do have a role to play in ensuring our Nation's laws and regulations keep pace and complement the biomedical research and innovation that is happening at lightning speed.